Ads
related to: when to treat familial hypercholesterolemiatrustedhippo.com has been visited by 100K+ users in the past month
Search results
Results from the WOW.Com Content Network
In January 2013, The US FDA also approved mipomersen, which inhibits the action of the gene apolipoprotein B, for the treatment of homozygous familial hypercholesterolemia. [47] [48] [49] Gene therapy is a possible future alternative. [50] Evinacumab, a monoclonal antibody inhibiting angiopoietin-like protein 3, was approved in 2021 for adjunct ...
This includes familial hypercholesterolemia (high cholesterol), familial hypertriglyceridemia (high triglycerides), and familial combined hyperlipidemia (high levels of both cholesterol and ...
Mipomersen (INN; trade name Kynamro) is a drug used to treat homozygous familial hypercholesterolemia and is administered by subcutaneous injection. There is a serious risk of liver damage from this drug and it can only be prescribed in the context of a risk management plan.
Statins remain a first-line treatment in familial hypercholesterolemia, [53] although other cholesterol-reducing measures may be required. [55] In people with homozygous deficiencies, statins may still prove helpful, albeit at high doses and in combination with other cholesterol-reducing medications. [56]
Family history, especially having a genetic disorder called familial hypercholesterolemia. ... Statins or other medications to treat high cholesterol levels. Medications to treat blood clots.
In the UK, after someone is diagnosed with familial hypercholesterolemia, clinicians, family, or both, contact first- and second-degree relatives to come forward for testing and treatment. Research suggests that clinician-only contact results in more people coming forward for testing.
Ads
related to: when to treat familial hypercholesterolemiatrustedhippo.com has been visited by 100K+ users in the past month